Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Expert Insights on Clinical Research

Clinical Research is the study of experimental therapies in human volunteers. Also referred to as clinical trials, clinical research is often funded by the NIH and/or pharmaceutical companies and regulated by the Food and Drug Administration within the United States. The purpose of clinical research is to study the safety and efficacy of therapies against a control such as a placebo or an existing, approved therapy.

Gerson Lehrman Group Council Members are available to discuss Clinical Research via phone consultations, live meetings, surveys, and other custom GLG products and services.

Find, engage, and manageSM experts today through the GLG platform

Featured Council Members

GLG Council Members are leading experts including academics, scientists, and industry specialists

Daniel Wynn, MD, Director of Clinical Research, CONSULTANTS IN NEUROLOGY LTD

Daniel Wynn, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Director of Clinical ResearchCONSULTANTS IN NEUROLOGY LTD

Warren Botnick, MD, President, PSS Clinical Research

Warren Botnick, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

PresidentPSS Clinical Research

Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER

Jeffrey WeinbergWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Director of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Mark Vandewalker, MD, Allergy Specialist and Partner, Allergy & Asthma Consultants Of The Ozarks Ltd

Mark Vandewalker, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Allergy Specialist and PartnerAllergy & Asthma Consultants Of The Ozarks Ltd

Charles Ryan, MD, Associate Professor of Medicine, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Charles Ryan, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Associate Professor of MedicineUNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Browse all 407 Leading Experts

Recent News Analyses

News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations

Starpharma gets US patent for use of VivaGel for protection against STIs

September 29, 2009

Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER

Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com

Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGelĀ® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves...

Stelara new Option for Psoriasis

September 26, 2009

Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER

Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com

The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability...

India is a good clinical trial destination with new CROs in future

September 27, 2009

Growing pharma market makes India a clinical trial destination: Report | www.thehindubusinessline.com

Pharmaceutical boom in India has opened up the doors of new clinical trials due to various factors, like new research & treatment avenues, which can be explored best in Indian Clinical Trials due to ease of carrying out Clinical trials in india, which is also giving birth to new CROs.

New hopes for Influenza Prevention & treatment

September 29, 2009

Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment | www.pipelinereview.com

Joint Strategic Collaboration between Johnson & Johnson and Crucell for influenza prevention and Treatment can open up new avenues by joint Joint research & clinical Trial programmes.

Pharma Outsourcing: Where Will it End?

November 3, 2009

Quintiles inks pharma deals | www.outsourcing-pharma.com

A major supplier of clinical development services has just been awarded all of Astra Zeneca's clinical pharmacology work. Such work was traditionally performed internally but is now one of many stages of development being outsourced. This follows similar trends in research, where pharma companies are...

Browse all 7647 GLG News Analyses

Contact Gerson Lehrman Group to engage a Clinical Research expert